Genetic Testing: Next Generation Sequencing
Customize your policy alerts
Sign up for Presbyterian Health Plan Policy 29.0 alerts
Get alerted when Policy 29.0 changes without checking for updates manually.
Monitor payer policy activity
This medical policy governs coverage and prior authorization for next-generation sequencing, including somatic and germline cancer testing, solid-tumor testing, and testing for myeloid malignancies or suspected myeloid malignancies. Coverage depends on the member's specific benefit plan and Schedule of Benefits and applies to Commercial, Medicaid, and Medicare products.
The 2025 annual review added CPT/PLA codes 0523U, 0473U, 0543U, and 0211U for NGS testing and requires prior authorization for them.
The policy continues prior authorization for the listed NGS, solid-tumor, and myeloid-malignancy testing codes.
The policy replaced CPT 81455 with CPT 81479 for the xT CDx colorectal-cancer and solid-organ-neoplasm laboratory test effective April 28, 2023.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.